Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment - PubMed (original) (raw)

Review

. 2006 Feb 20;24(6):988-94.

doi: 10.1200/JCO.2005.05.2456. Epub 2006 Feb 6.

Affiliations

• PMID: 16461779
• DOI: 10.1200/JCO.2005.05.2456

Review

Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment

Maurie Markman et al. J Clin Oncol. 2006.

No abstract available

PubMed Disclaimer

Similar articles

• Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
  Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A, Young RC. Ozols RF, et al. Gynecol Oncol. 2006 Oct;103(1):1-6. doi: 10.1016/j.ygyno.2006.06.026. Epub 2006 Aug 10. Gynecol Oncol. 2006. PMID: 16904166 No abstract available.
• Understand the benefits and risks of intraperitoneal therapy for advanced ovarian cancer.
  Oestreicher P. Oestreicher P. ONS Connect. 2007 Apr;22(4):24-5. ONS Connect. 2007. PMID: 17477008 No abstract available.
• The role of intraperitoneal chemotherapy in ovarian cancer.
  Markman M. Markman M. Clin Adv Hematol Oncol. 2006 Nov;4(11):809-10. Clin Adv Hematol Oncol. 2006. PMID: 17143249 Review. No abstract available.
• Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
  Petignat P, du Bois A, Bruchim I, Fink D, Provencher DM. Petignat P, et al. Crit Rev Oncol Hematol. 2007 May;62(2):137-47. doi: 10.1016/j.critrevonc.2006.11.009. Epub 2006 Dec 26. Crit Rev Oncol Hematol. 2007. PMID: 17188887 Review.
• Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
  Bae JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, Ahn WS, Namkoong SE. Bae JH, et al. Gynecol Oncol. 2007 Jul;106(1):193-200. doi: 10.1016/j.ygyno.2007.03.019. Epub 2007 Apr 26. Gynecol Oncol. 2007. PMID: 17466362

Cited by

• Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer.
  Wang JY, Gross M, Urban RR, Jorge S. Wang JY, et al. Curr Treat Options Oncol. 2024 Mar;25(3):313-329. doi: 10.1007/s11864-023-01171-3. Epub 2024 Jan 4. Curr Treat Options Oncol. 2024. PMID: 38270801 Review.
• Multiple isolated ovarian cancer recurrences in the cervix and vagina after supracervical hysterectomy: A case report.
  Nguyen AQ, Ehmann S, Feinberg J, Tew WP, Carthew K, Sonoda Y, Chi DS. Nguyen AQ, et al. Gynecol Oncol Rep. 2022 May 23;41:101006. doi: 10.1016/j.gore.2022.101006. eCollection 2022 Jun. Gynecol Oncol Rep. 2022. PMID: 35663846 Free PMC article.
• Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy.
  Nakamura K, Yoshikawa N, Mizuno Y, Ito M, Tanaka H, Mizuno M, Toyokuni S, Hori M, Kikkawa F, Kajiyama H. Nakamura K, et al. Cancers (Basel). 2021 Mar 7;13(5):1141. doi: 10.3390/cancers13051141. Cancers (Basel). 2021. PMID: 33799991 Free PMC article.
• Modeling of Chemoperfusion vs. Intravenous Administration of Cisplatin in Wistar Rats: Adsorption and Tissue Distribution.
  Kireeva G, Kruglov S, Maydin M, Gubareva E, Fedoros E, Zubakina E, Ivanenko N, Bezruchko M, Solovyev N. Kireeva G, et al. Molecules. 2020 Oct 15;25(20):4733. doi: 10.3390/molecules25204733. Molecules. 2020. PMID: 33076418 Free PMC article.
• Survival and recurrence after intraperitoneal chemotherapy use: Retrospective review of ovarian cancer hospital registry data.
  Adambekov S, Lopa S, Edwards RP, Lemon L, Wang S, Taylor SE, Orr B, Linkov F. Adambekov S, et al. Cancer Med. 2020 Oct;9(20):7388-7397. doi: 10.1002/cam4.3340. Epub 2020 Aug 19. Cancer Med. 2020. PMID: 32813321 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information